← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	2,358	+8	+0.3%	$233B
2	2 Pfizer PFE $166B	2,042	-8	-0.4%	$151B
3	3 Merck MRK $364B	1,924	-2	-0.1%	$130B
4	4 AbbVie ABBV $501B	1,798	+35	+2%	$99.5B
5	5 Bristol-Myers Squibb BMY $121B	1,642	+47	+3%	$73.7B
6	6 Amgen AMGN $230B	1,606	+10	+0.6%	$108B
7	7 Gilead Sciences GILD $190B	1,505	-16	-1%	$81.5B
8	8 Novartis NVS $279B	938	+17	+2%	$22.2B
9	9 GSK GSK $95.9B	742	-38	-5%	$9.86B
10	10 Regeneron Pharmaceuticals REGN $80.1B	606	+2	+0.3%	$32.3B
11	11 Incyte INCY $22.6B	496	+3	+0.6%	$22.6B
12	12 AstraZeneca AZN $251B	456	-11	-2%	$12.8B
13	13 Jazz Pharmaceuticals JAZZ $13.6B	303	-16	-5%	$8.03B
14	14 DELISTED Exact Sciences EXAS	282	+16	+6%	$4.71B
15	SGEN 15 DELISTED Seagen Inc. Common Stock SGEN	268	-33	-11%	$7.81B
16	16 Exelixis EXEL $15.1B	264	+15	+6%	$5.88B
17	CLVS 17 DELISTED Clovis Oncology, Inc. CLVS	255	-16	-6%	$4.15B
18	18 Opko Health OPK $1.02B	234	+2	+0.9%	$902M
19	19 Myriad Genetics MYGN $397M	220	-19	-8%	$2.72B
20	20 Qiagen QGEN $9.41B	215	+4	+2%	$4.49B
21	21 Kyntra Bio KYNB $22.5M	182	+31	+21%	$2.58B
22	22 DELISTED Immunogen Inc IMGN	180	+23	+15%	$691M
23	23 Puma Biotechnology PBYI $527M	171	+17	+11%	$4.39B
24	24 DELISTED Eagle Pharmaceuticals, Inc. EGRX	169	-6	-3%	$947M
25	25 Halozyme HALO $13.3B	166	-1	-0.6%	$2.11B